DOAC dosing in renal impairment and obesity
Contents
Renal function determines DOAC eligibility and dose. Use Cockcroft-Gault (not eGFR) — the trials used CG, and the two methods diverge meaningfully at extremes of age and weight. Dabigatran is the most renally dependent (80% renal clearance). For obesity, ISTH 2021 supports standard-dose DOACs for most patients up to ~150 kg / BMI ~50; beyond that, evidence thins and warfarin or anti-Xa monitoring may be warranted.
renal dosing — use cockcroft-gault
All DOAC trials used Cockcroft-Gault CrCl for dose selection. eGFR (CKD-EPI) overestimates renal function in the elderly and underestimates it in the obese. Using eGFR risks inappropriate dose selection — always calculate CG-CrCl for DOAC dosing decisions.
Cockcroft-Gault: CrCl = [(140 − age) × weight (kg) × (1.04 if female)] / serum creatinine (µmol/L)
- Use actual body weight (not ideal or adjusted) — this is what the trials used
- In AKI or rapidly changing creatinine, CG is unreliable — hold DOACs and use parenteral anticoagulation
dose adjustments by crcl
AF indication
| agent | standard dose | reduced dose criteria | reduced dose | avoid |
|---|---|---|---|---|
| apixaban | 5 mg BID | ≥2 of: age ≥80, weight ≤60 kg, Cr ≥133 µmol/L | 2.5 mg BID | CrCl <15 |
| rivaroxaban | 20 mg OD (with food) | CrCl 15–49 | 15 mg OD | CrCl <15 |
| dabigatran | 150 mg BID | age ≥80, or concurrent verapamil | 110 mg BID | CrCl <30 |
| edoxaban | 60 mg OD | CrCl 15–50, weight ≤60 kg, or P-gp inhibitor | 30 mg OD | CrCl <15 or >95 |
VTE treatment
| agent | acute phase | maintenance | renal caution |
|---|---|---|---|
| apixaban | 10 mg BID × 7d | 5 mg BID | no dose reduction for CKD; avoid CrCl <15 |
| rivaroxaban | 15 mg BID × 21d | 20 mg OD | avoid CrCl <15; limited data CrCl 15–29 |
| dabigatran | after ≥5d parenteral | 150 mg BID | avoid CrCl <30 |
| edoxaban | after ≥5d parenteral | 60 mg OD (30 mg if CrCl 15–50 or ≤60 kg) | avoid CrCl <15 |
The apixaban AF dose reduction requires ≥2 of 3 criteria (age ≥80, weight ≤60 kg, Cr ≥133). CrCl alone does NOT trigger dose reduction — a 75-year-old 80 kg patient with CrCl 20 still gets 5 mg BID for AF. Inappropriate dose reduction is the most common DOAC prescribing error and is associated with increased stroke risk.
severe CKD and dialysis
| CrCl | options |
|---|---|
| 15–29 | apixaban 5 mg BID (AF — no dose reduction for CrCl alone); rivaroxaban 15 mg OD (AF, limited data); avoid dabigatran |
| <15 / dialysis | warfarin (standard of care); apixaban 5 mg BID is approved by Health Canada for AF on dialysis based on PK data, but clinical outcome data are limited and conflicting |
- Apixaban has the least renal clearance (27%) → most data and regulatory support in severe CKD
- Dabigatran (80% renal) is the most dangerous in renal failure — contraindicated at CrCl <30
- Monitor renal function — check CrCl at baseline, at 3 months, then every 6–12 months (more frequently if CrCl <30 or intercurrent illness)
obesity
current evidence and thresholds
| weight range | recommendation |
|---|---|
| ≤120 kg / BMI ≤40 | standard DOAC doses — well-represented in RCTs |
| 120–150 kg / BMI 40–50 | standard doses acceptable — ISTH 2021 updated guidance supports DOACs; consider anti-Xa trough level for reassurance |
| >150 kg / BMI >50 | limited data — consider warfarin or heparins with anti-Xa monitoring; if DOAC used, check anti-Xa trough |
- ISTH 2021 shifted from the previous 2016 recommendation (which cautioned against DOACs at >120 kg) based on accumulating real-world data
- Post-bariatric surgery: absorption may be unpredictable (especially for rivaroxaban, which requires food and has variable absorption in altered anatomy) — use warfarin or LMWH, or check anti-Xa levels if DOAC used
anti-xa monitoring
Used for reassurance in extremes of weight or renal function — not routine.
| agent | expected trough (steady state) |
|---|---|
| apixaban 5 mg BID | 50–150 µg/L |
| rivaroxaban 20 mg OD | 20–100 µg/L (trough, 24h post-dose) |
| edoxaban 60 mg OD | 20–80 µg/L |
- Measure trough (just before next dose) at steady state (day 3+)
- Sub-therapeutic levels → consider dose increase or switch to warfarin
- Supra-therapeutic levels → re-evaluate indication and dose
For patients 120–150 kg: start standard-dose apixaban (best safety profile), check anti-Xa trough at steady state. If within range → continue. If sub-therapeutic → discuss with haematology. For >150 kg: default to warfarin with INR monitoring unless specific circumstances favour a DOAC with level monitoring.
traps
- Using eGFR instead of Cockcroft-Gault — the most common systemic error. eGFR overestimates CrCl in elderly patients → may miss dose reduction criteria. Hospital EMRs often display eGFR prominently; CG-CrCl usually requires manual calculation.
- Inappropriate apixaban dose reduction — reducing to 2.5 mg BID based on CrCl alone (without meeting ≥2 of 3 criteria) leaves patients under-anticoagulated and at higher stroke risk. This error is more dangerous than not reducing.
- Dabigatran in fluctuating renal function — CrCl can drop during illness, dehydration, or AKI. A patient stable at CrCl 35 can easily drop to <30 during a hospital admission → hold dabigatran, switch to parenteral.
- Edoxaban at high CrCl — counterintuitively, edoxaban is less effective at CrCl >95 (higher clearance → sub-therapeutic levels) — do not prescribe for AF in patients with normal-high renal function.
- Post-bariatric absorption — Roux-en-Y and sleeve gastrectomy alter GI transit and absorption surface area. Rivaroxaban post-pyloric absorption drops 29–56%. If a DOAC is chosen post-surgery, apixaban (absorbed throughout the GI tract) is preferred over rivaroxaban.
related: DOACs · warfarin · heparins · acute kidney injury · periprocedural anticoagulation